News | March 10, 2026
AbbVie reports promising early results for novel obesity therapy ABBV-295
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
ShunzymeX leverages a proprietary protease to streamline purification
Subscribe To Our Newsletter & Stay Updated
